Statin Adherence & Type 2 Diabetes Risk | NDEI

Click here for the Slide Library.
Click here to return to

  • This cohort study investigated the relationship between increasing levels of statin adherence and type 2 diabetes.
  • Subjects were from the database of National Health Service in Italy and had ≥1 new statin prescription and no prior diabetes (N=115,709).
  • Adherence was assessed by proportion of days covered (PDC): the cumulative number of days medication was available divided by days of follow-up.
    • Adherence was categorized as very low (PDC <25%), low (PDC 25-49%), intermediate (PDC 50-74%), and high (PDC ≥75%)
    • PDC categories also considered based on statin potency: rosuvastatin ≥10 mg, atorvastatin ≥20 mg, and simvastatin ≥40 mg considered higher potency; all other statins classified as lower potency
  • The study outcomes were initiation of antihyperglycemic therapy or hospitalization for type 2 diabetes.

Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225-2232.

Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.

August 2014

This slide was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.